XXXX : changing expectations?

@entity1 @entity13850 @entity0 @entity5 @entity11 @entity2903 @entity463 @entity3866 @entity2213
@entity463 ( @entity463 ) represents the most aggressive @entity11 in the adult population. Despite recent research efforts, the prognosis of @entity1 with @entity463 has remained dismal. Lately, the knowledge of genetic information about gliomagenesis has increased; we even have a classification of the genetic expression of the @entity5 . The main problem is that at the moment we do not have any therapeutical resources to help us better treat these @entity5 , as we can do, with others @entity5 like @entity0 . We have also improved on diagnostic imaging, especially with the new MRI sequences; we can now better define the characteristics of the @entity5 area and the surrounding brain structures, allowing us to adjust resections. Thanks to the most advanced surgery techniques, such as neuronavigation, intraoperative control of the nervous function and the @entity5 volume, the neurosurgeon is able to complete @entity5 exeresis with less morbidity. These imaging techniques allow the radiation oncologist to better contour the irradiation target volume, the structures and the organs at risk, to diminish the irradiation of apparently healthy tissue. Nowadays, knowledge of brain stem cells provides new expectations for future treatments. Novel targeted agents such as bevacizumab, @entity2213 , @entity3866 , @entity13850 , immunotherapy, cilengitide, talampanel, etc. are helping classical chemotherapeutic agents, like @entity2903 , to achieve an increase in overall survival. The main objective is to improve median overall survival, which is currently between 9 and 12 months, with a good quality of life, measured by the ability to carry out daily life activities.
